Please login to the form below

Not currently logged in
Email:
Password:

Jardiance

This page shows the latest Jardiance news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

risk of lower-limb amputation in diabetics, putting it at a disadvantage compared to rival SGLT2 drugs such as Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca’s Farxiga

Latest news

More from news
Approximately 17 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth. ... In contrast Jardiance and Vipidia are still growing where Jardiance (the 3rd entrant SGLT2) appears to have overtaken

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics